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Abstract
Objective:
The aim of this study was to assess the efficacy and tolerability of tapentadol (TP) for a period of 4 weeks in
patients who were already treated by opioids.
Methods:
A convenience sample of 30 patients was selected for a prospective observational cohort study. Cancer
patients who were receiving at least 60mg of oral morphine equivalents were selected. Patients
discontinued their previous opioid analgesics before starting TP, in doses calculated according the
previous opioid consumption (1:3.3 ratio with oral morphine equivalents). The subsequent doses were
changed according to the patients’ needs for a period of 4 weeks. Oral morphine was offered as a
breakthrough pain medication. Pain and symptom intensity were recorded at weekly intervals. Distress
score (DS) was calculated from the sum of symptom intensities. TP opioid escalation indexes (TPEI) for the
study period were calculated.
Results:
Nineteen patients were male, and the mean age was 63.5 years (11.5). The mean Karnofsky status was
62.9 (10). The mean dose of oral morphine equivalents before switching to TP was 112mg (57) and the
initial mean dose of TP was 343mg (150). Pain intensity significantly decreased. Tapentadol escalation
index in percentage was 1.26 (TPEI% 2.6) and Tapentadol escalation index in mg was 2.76
(TPEImg 4.96). No significant relationships were found with primary tumor (TPEI%, p¼ 0.204;
TPEImg, p¼ 0.180), pain mechanism (TPEI%, p¼ 0.863; TPEImg, p¼ 0.846), age (TPEI%, p¼ 0.882;
TPEImg, p¼ 0.884), or gender (TPEI%, p¼ 0.287; TPEImg, p¼ 0.325). DS decreased, but non-
significantly (p¼ 0.1). Ten patients did not complete the study period: five patients discontinued TP for
uncontrolled pain, despite increasing doses of TP over 600mg/day. Two patients discontinued TP for
adverse effects and three patients dropped out, one patient for poor compliance and two patients for
unrecorded reasons.
Conclusion:
In our sample, TP used in doses of 350–450mg/day was well tolerated and effective in opioid tolerant
patients with cancer pain and could be considered as a flexible drug to be used for the management of
moderate to severe cancer pain. Like most studies in patients with cancer pain, it was limited by its open-
label, uncontrolled design, the number of patients lost in follow-up, and discontinuation of the treatment for
several reasons. Further studies in a large number of patients should confirm these preliminary results.
Introduction
Cancer pain management is based on a sequential approach of drugs, suggested
by WHO, through steps corresponding to drugs with different potencies.
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The application of the WHO three-step analgesic ladder
has been reported to provide satisfactory pain relief in up to
90% of patients with cancer pain1. Opioids are the corner-
stone of analgesic therapy in cancer patients with chronic
pain. Opioids produce analgesia by binding to opioid
receptors in the central nervous system. These receptors
are inhibitory, as their activation hyperpolarizes neurone
transmitter release in the dorsal horn of the spinal cord,
interrupting the transmission of pain signals from incom-
ing fibers by their presynaptic inhibitory action, and also
reduces spinal neuronal activity through postsynaptic
receptors. However, opioids also produce various adverse
effects. New analgesics have been developed with the pur-
pose of improving the pharmacological profile of opioids,
by reducing adverse effects.
Tapentadol (TP) is a centrally analgesic agent
acting with two mechanisms of action: mu-opioid receptor
agonism and norepinephrine reuptake inhibition. The
moderate affinity to mu receptors and the opioid-sparing
effect of inhibition of norepinephrine reuptake suggest
that TP should produce fewer opioid-related adverse
effects than typical mu-agonists2. TP has been shown
to be effective in different pain models3–5. TP has been
developed for the management of moderate to severe
chronic pain. In humans, efficacy and safety of TP have
been shown in comparative studies with placebo and
oxycodone in several non-malignant conditions. A
recent systematic review of TP trials clearly shows that
for certain domains fewer adverse effects are reported.
The benefit ratio of tapentadol appears to be better com-
pared to other strong opioids6. Recent recommendations
did not include this new drug, because it was made
available after their development7. Based on literature
research, there is a paucity of information regarding the
efficacy and tolerability in cancer pain management.
In preliminary studies, TP has been found to be effect-
ive and well tolerated in the management of opioid-naı¨ve
patients with cancer pain8,9. However, cancer patients
with pain often require changes in opioid therapy during
the course of disease, due to disease factors and pain char-
acteristics as well as prolonged use of opioids, in an attempt
to improve the analgesic response or reduce adverse effect
intensity10. The anti-hyperalgesic effects of TP could be
potentially helpful in states of hyperexcitation such as
those observed in patients who have received multiple
trials of opioids unsuccessfully11. In the literature no data
are available on the use of TP in patients who are tolerant
to opioids and may require higher doses of TP than those
reported in existing studies. The highest suggested dose is
500 mg/day. However, this information is not supported by
specific studies. TP could be of benefit in patients requiring
relatively high doses of opioids, because of its dual anal-
gesic effect due to its pharmacological characteristics. The
aim of this study was to assess the efficacy and tolerability
of TP for a period of 4 weeks in cancer patients who were
already receiving strong opioids.
Methods
A prospective study was carried out in a convenience
sample of consecutive cancer patients admitted to an
acute palliative care unit in Palermo and a home care pro-
gram in L’Aquila for a period of 1 year, from January to
December 2013. For recruitment medical staff asked
patients to participate. Informed consent and institutional
approval were obtained.
The study included patients who were at least 18 years
of age, had a diagnosis of cancer pain, were receiving at
least 60 mg/day of oral morphine equivalents. A WHO
step III analgesic must have been required for the manage-
ment of cancer pain with an intensity of more than 4 on an
11 point numerical rating scale (0¼ ‘no pain’ to 10¼ ‘pain
as bad as you can imagine’), or because of the occurrence of
adverse effects, or for convenience (see below). Exclusion
criteria included the following: a history of or laboratory
values reflecting severe renal or hepatic impairment,
patients who were receiving monoamine oxidase inhibi-
tors within 14 days prior to screening or non-stable doses of
selective serotonin reuptake inhibitors. The same proto-
cols and modality of drug administration were provided in
inpatient unit and home care patients. Patients were vis-
ited or contacted telephonically at least every 2 days to
monitor and eventually changing the treatment.
Patients stopped taking their previous opioid analgesics
before receiving their first dose of TP. An oral morphine
equivalent dose of the previous opioid was determined for
each patient using current tables for opioid conversion
used in the unit10. The calculated dose was converted to
TP, using a conversion rate of 3.3, according to previous
findings12. Doses were then rounded according to existing
dose tablets. The subsequent doses were flexible and were
changed according to the clinical situation to find the best
balance between pain and opioid-related symptoms,
according to the amount of drugs consumed as rescue
doses in the previous day and clinical judgment. Oral mor-
phine was offered as a breakthrough pain medication.
Adjuvant drugs, previously administered to control symp-
toms due to illness or treatment, were continued at the
same doses during switching, or were administered to
assist opioid switching in case of need. Non-opioid anal-
gesics were also continued if previously administered, at
the same doses. No patient received anticancer therapy
during the course of the study.
For each patient the following data were measured at
weekly intervals for 4 weeks:
(a) Pain intensity measured using patients’ self report on
a numerical scale from 0 to 10.
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(b) Symptoms associated with opioid therapy or com-
monly present in advanced cancer patients – such
as nausea and vomiting, drowsiness, confusion, con-
stipation, dry mouth, myoclonus, sweating – using a
scale from 0 to 3, corresponding to a verbal scale (not
at all, slight, a lot, awful), were recorded. A distress
score (DS) was also calculated as a sum of symptom
intensity. Although never validated, this score
has been used previously in different studies for deter-
mining the ‘weight’ of adverse effects. Symptoms
were assessed by the patient, whenever possible, at
time of switching and at week intervals for four
weeks.
(c) Previous daily opioid doses (oral morphine equiva-
lents), doses of TP, and DS before switching (T0),
and at weekly intervals for 4 weeks (T1–4).
(d) TP escalation index percent (TPEI%) was calculated
at T4. This score expresses the mean increase of
opioid dosage percent from opioid starting dose
(TPSD), according the following formula: ([TPMD
- TPSD]/TPSD)/days 100, where TPMD is the
maximal dose of TP. TP escalation index in mg
(TPEImg) was calculated as the mean increase of
TP dosage in mg using the following formula:
(TPMD - TPSD)/days8,13.
Patients who were switched to TP were divided into
four categories, according to previous research
experience10:
(a) Patients presenting relevant adverse effects despite
good pain control.
(b) Patients with a poor analgesic response despite
having their dose doubled in 1 week.
(c) Patients with both poor pain control and prevalent
adverse effects.
(d) Patients who were switched for patient’s preference
and/or convenience, because they had adequate pain
control and acceptable adverse effects.
Age, gender, primary cancer, and performance status
were recorded.
Statistical analysis
Data were analyzed with IBM SPSS Software 21.0 ver-
sion (SPSS Inc., Chicago, IL, USA) and Epi Info
software, version 3.2.2 (Centers for Disease Control
and Prevention). Statistical analysis of quantitative and
qualitative data, included descriptive statistics, was per-
formed for all the items. The paired samples Student’s
t-test was used to compare opioid mean dose in the
four weekly periods. The paired Wilcoxon signed-rank
test was used to compare pain intensity scores and symp-
tom intensity scores in the four weekly periods. The
one-way analysis of variance (ANOVA) and Kruskal
Wallis statistic test were used to evaluate the differences
in TPEI% and TPEImg for parametric and nonparametric
variables, respectively. All p values were two-sided and
p values less than 0.05 were considered to indicate stat-
istical significance.
Results
From a sample of 732 consecutive patients, admitted as
inpatients (n¼ 502) and home care (n¼ 230), assessed
in 1 year, 30 patients who were receiving at least 60 mg/
day of oral morphine equivalents gave consent to take part
in the study in a period of 1 year. Eleven and nineteen
patients were recruited in inpatient units and home care,
respectively (Figure 1). Nineteen patients were male
(63%), and the mean age was 63.5 years (SD 11.5). The
mean Karnofsky status was 62.9 (SD 10). Primary tumors
were in a rank order: lung (n¼ 12), urogenital (n¼ 6),
gastrointestinal (n¼ 3), head–neck (n¼ 3), liver (n¼ 2),
myeloma (n¼ 2), and breast (n¼ 2). Mixed pain mechan-
isms (nociceptive and neuropathic pain) were found in the
majority of patients (n¼ 19), pure neuropathic pain mech-
anism was observed in one patient, while the remaining
ten patients had nociceptive pain.
The majority of patients were switched to TP from oral
morphine (n¼ 23), five patients were switched from
hydromorphone and two patients from transdermal fen-
tanyl. Eighteen patients were started with TP for poor
pain control (60%), eight patients for convenience,
one patient for adverse effects (26.6%), and three patients
for poor pain control and adverse effects (10%).
The mean dose of oral morphine equivalents before
switching to TP was 112.2 mg (SD 57.4). The initial
mean dose of TP was 343.3 mg (SD 150.1). Seven patients
732 admitted patients
30 patients receiving >60 mg of oral morphine
consenting to participate, switching to TP
Home care (n = 19)Inpatients (n = 11)
Home care (n = 230)Inpatients (n = 502)
n = 18, poor pain control
n = 8, convenience
n = 3, poor pain control and adverse effects
n = 1, adverse effects
10 patients discontinued:
n = 5, uncontrolled pain despite dose escalation
n = 2, adverse effects
n = 3, dropped out
20 patients completed the 4 week period 
Figure 1. Patient flow chart.
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received 600 mg/day of TP. None of them dropped out
because of adverse effects. One of them changed treatment
due to inefficacy in controlling pain. TPEI% was 1.26 (SD
2.6) and TPEImg was 2.76 (SD 4.96). No significant rela-
tionships were found with primary tumor (TPEI%,
p¼ 0.204; TPEImg, p¼ 0.180), pain mechanism
(TPEI%, p¼ 0.863; TPEImg, p¼ 0.846), age (TPEI%,
p¼ 0.882; TPEImg, p¼ 0.884), or gender (TPEI%,
p¼ 0.287; TPEImg, p¼ 0.325). Doses of TP, pain inten-
sity, and DS at week intervals are described in Table 1. TP
doses significantly increased (p¼ 0.05), while pain inten-
sity significantly decreased (p¼ 0.001). A non-significant
decrease in DS was reported (p¼ 0.1). The numbers of
patients presenting opioid-related symptoms with an
intensity of 2–3 and receiving adjuvants at the different
time intervals are reported in Table 2. A significant
decrease in constipation was observed (p¼ 0.031).
Ten patients (33%) did not complete the study period.
Globally, five patients discontinued TP for uncontrolled
pain, despite increasing doses of TP. Two patients discon-
tinued TP for adverse effects and three patients dropped
out: one patient for poor compliance and two patients for
unrecorded reasons.
Discussion
The present study evaluated TP in opioid-tolerant patients
with higher starting doses than those commonly used in
opioid-naı¨ve patients. The doses were calculated from the
previous opioid consumption, with a conversion ratio with
morphine of 3.3. Pain intensity significantly decreased to
acceptable levels during the study period. The dose of TP,
given according to patients’ clinical response, slowly
increased over 4 weeks, with low escalation indexes.
TPEI% and TPEImg calculated in this study were similar
to those observed in opioid-naı¨ve patients in a similar
study period of 4 weeks8, despite TP being started in
patients who were already tolerant to opioids, with doses
of more than 300 mg/day. The final doses of TP recorded at
the end of the study were significantly higher and were still
effective in most patients. The initial ratio, suggested by
previous experience, was as safe as effective. Indeed, it was
already necessary after a week in most cases to increase TP
doses. This is justified by the majority of patients who
entered the study for poor pain control, despite receiving
other strong opioids in mean doses of more than 110 mg of
oral morphine equivalents, unsuccessfully.
Data regarding TP in cancer patients are limited. After
an open-label preliminary report in opioid-naı¨ve patients8,
Table 1. Previous opioid doses (OME, oral morphine equivalents), tapentadol (TAP) doses, pain intensity, and DS (see text) at time intervals: T0¼ baseline,
T1¼ 1st week, T2¼ 2nd week, T3¼ 3rd week, T4¼ 4th week.
N patients T0 T1 T2 T3 T4 p
30 30 28 22 20
Opioid dose (OME) mg 112 (57)
TAP dose mg 343 (150) 431 (163)* 435 (201) 409 (208 427 (178) 0.001 T1 vs T0
0.013 T2 vs T0
0.077 T3 vs T0
0.028 T4 vs T0
Pain 5 (1.8) 2.7 (2.1)* 2.7 (1.9)* 2.5 (1.7)* 2.6 (1.6)* 50.0005 T1 vs T0
50.0005 T2 vs T0
0.001 T3 vs T0
0.002 T4 vs T0
DS 3.3 (2.4) 3.3 (2.6) 3 (2) 2.6 (1.9) 2.3 (1.8) 0.675 T1 vs T0
0.961 T2 vs T0
0.438 T3 vs T0
0.566 T4 vs T0
*indicates those values which are statistically significant.
Table 2. Number of patients with the most important opioid-related
symptoms with intensity 2–3 and frequency of use of adjuvants at time
intervals: T0¼ baseline, T1¼ 1st week, T2¼ 2nd week, T3¼ 3rd week,
T4¼ 4th week.
N patients T0 T1 T2 T3 T4 p*
30 30 28 22 20
Nausea 1 2 0 0 1 0.558
Drowsiness 2 2 2 0 0 0.406
Dry Mouth 13 10 10 7 7 0.820
Constipation 10 5 4 1 1 0.031*
Confusion 0 0 0 0 0
Myoclonus 0 0 0 0 0
Sweating 0 0 0 0 0
Antiemetics 8 7 5 3 3 0.737
Laxatives 11 9 9 4 3 0.384
Corticosteroids 7 8 7 5 4 0.987
Antidepressants 5 5 6 5 6 0.789
Anticonvulsants 13 12 10 10 10 0.886
Neuroleptics 0 2 1 1 2 0.537
Benzodiazepines 0 0 1 0 0 0.452
NSAIDs/paracetamol 9 7 5 4 2 0.506
*Paired Wilcoxon signed-rank test.
*indicates those values which are statistically significant
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only two other trials were published. In a well powered,
randomized, double-blind study performed in opioid-naı¨ve
cancer patients for 4 weeks, TP in doses of 25–200 mg/day
provided similar analgesic efficacy and a better gastrointes-
tinal tolerability compared to oxycodone in doses of
5–40 mg/day9. In a double-blind controlled study, patients
were initiated with TP 100–250 mg/day, or morphine
40–100 mg/day. After a titration period, TP patients
were treated with placebo or TP, while patients on mor-
phine continued the same treatment, for a maintenance
period of 4 weeks. Small differences with placebo were
found, possibly because of the use of as needed medications
which flattened the pain intensity levels. TP and mor-
phine provided similar analgesic efficacy in modal daily
doses of 300 mg and 120 mg, respectively (ratio 2.5:1)13.
In both studies information regarding higher TP doses
is lacking.
TP could be particularly attractive for patients with
neuropathic pain5,11,14. TP was equally effective regardless
of the mechanisms assessed by clinical judgment.
However, the relatively low number of patients participat-
ing in this preliminary trial does not allow definite infor-
mation to be obtained, and trials with a larger number of
patients could identify subclasses of patients who could
benefit from TP. In a previous study with a large number
of patients, for the subgroup of patients with a neuropathic
pain component, responder rates during the maintenance
period were 73.5% in the TP group, and 67.6% in the
morphine group15. This point needs to be better deter-
mined with a more selected population.
TP was relatively well tolerated. One-third of patients
discontinued TP for alternative treatments, particularly
when further dose increments were ineffective, or because
of poor compliance with TP therapy. Only two patients
dropped out because of adverse effects. This rate was con-
sidered acceptable, given the reported need to switch to
other opioids from morphine due to unfavorable responses
in the cancer population, and the different levels of TP
dosage, never reported before, used in a context of
increased requirements of opioid dosing16,17. Seven
patients received an off-label high dose, which was well
tolerated until the end of the study, except for one
patient who changed treatment due to inefficacy in
controlling pain. No symptoms possibly linked to inhib-
ition of norepinephrine reuptake at such high doses
were recorded. In a controlled study with placebo and
morphine, TP was generally well tolerated, with a low
incidence of adverse effects leading to discontinuation
during both the titration and maintenance periods.
During titration, the incidence of gastrointestinal adverse
effects was lower in the TP group than in the morphine
group15.
The use of adjuvant drugs administered prior to enter-
ing the study or symptomatic drugs did not change or
decreased during the study period, confirming the efficacy
and tolerability of the drug, particularly regarding gastro-
intestinal adverse effects, which are frequently associated
with opioid therapy18. In this study a decrease in the fre-
quency of constipation was observed.
This study confirms previous data obtained in observa-
tional and comparison studies with TP in cancer
patients6,8,15. These findings require confirmation in con-
trolled studies with a larger number of patients with differ-
ent levels of opioid consumption. The present data should
be interpreted with caution, because preliminary and
obtained in a low number of patients. Like most studies
in patients with cancer pain, it was limited by its open-
label, uncontrolled design, the number of patients lost to
follow-up, and discontinuation of the treatment for several
reasons.
Adjuvant analgesics could have influenced the
effects of TP, although doses were unchanged per protocol.
More data on different kinds of cancer population are
needed, for example patients with a lower performance
status or specific cancer pain syndromes. Finally, the
possible role of TP as add-on therapy should be
investigated.
Conclusion
TP used in doses of 350–450 mg/day was well tolerated and
effective in opioid tolerant patients with cancer pain and
could be considered as a flexible drug to be used for the
management of moderate to severe cancer pain. In patients
tolerant to mean doses of oral morphine equivalents of
more than 110 mg/day, TP dose increases were effective
in improving analgesia while maintaining adverse effect
intensity at acceptable levels without increasing the use
of adjuvants. Further studies in a large number of patients
should confirm these preliminary results.
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